CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
CRISPR Therapeutics AG reports 2018 executive compensation
By ExecPay News
Published: April 30, 2019
CRISPR Therapeutics AG reported fiscal year 2018 executive compensation information on April 30, 2019.
In 2018, five executives at CRISPR Therapeutics AG received on average a compensation package of $4M, a 9% increase compared to previous year.
Average pay of disclosed executives at CRISPR Therapeutics AG
Samarth Kulkarni, Chief Executive Officer, received $9.7M in total, which increased by 40% compared to 2017. 91% of Kulkarni's compensation, or $8.8M, was in option awards. Kulkarni also received $362K in non-equity incentive plan, $515K in salary, as well as $9.6K in other compensation.
Tony W. Ho, EVP, Research and Development, received a compensation package of $4.1M, which decreased by 7% compared to previous year. 84% of the compensation package, or $3.5M, was in option awards.
James R. Kasinger, General Counsel, earned $3.2M in 2018, a 123% increase compared to previous year.
Michael J. Tomsicek, Chief Financial Officer, received $2.3M in 2018, which increases by 4% compared to 2017.
Rodger Novak, President, earned $646K in 2018, a 81% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 30, 2019.